GC Green Cross Secures Product Approval for Hunter Syndrome Treatment in India and Taiwan

Hunterase IV Approved in 14 Countries Worldwide

"Expanding Presence in the Global Rare Disease Treatment Market"

GC Green Cross announced on August 24 that its Hunter syndrome treatment 'Hunterase IV' has obtained product approval from the Central Drugs Standard Control Organization (CDSCO) of India and the Taiwan Food and Drug Administration (TFDA). Additionally, the intraventricular administration formulation 'Hunterase ICV' has also been approved for product registration by the Taiwan TFDA.

With this, Hunterase IV has now been approved in a total of 14 countries worldwide, and Hunterase ICV has obtained product approval in a total of 4 countries.

GC Green Cross Headquarters View. GC Green Cross

India has a low rate of patients receiving existing treatments, making it a market with high unmet medical needs and significant growth potential. Taiwan, where both the IV and ICV formulations have received approval, is considered a country with excellent market accessibility due to its well-established early screening and patient support systems for Hunter syndrome.

GC Green Cross plans to further expand its presence in the global rare disease treatment market moving forward.

Lee Jaewoo, Head of Development at GC Green Cross, said, "We will continue to do our best to help improve patients’ quality of life."

This content was produced with the assistance of AI translation services.